Standard
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. / Pharoah, Paul D P; Palmieri, Rachel T; Ramus, Susan J; Gayther, Simon A; Andrulis, Irene L; Anton-Culver, Hoda A; Antonenkova, Natalia; Antoniou, Antonis C; Bcfr Investigators, Study Group Of; Beattie, Mary S; Beckmann, Matthias W; Birrer, Michael J; Bogdanova, Natalia; Bolton, Kelly L; Brewster, Wendy; Brooks-Wilson, Angela; Brown, Robert; Bützow, Ralf; Caldes, Trinidad; Caligo, Maria A; Campbell, Ian G; Chang-Claude, Jenny; Chen, Y Ann; Chenevix-Trench, Georgia; Cook, Linda S; Couch, Fergus J; Cramer, Daniel W; Cunningham, Julie M; Despierre, Evelyn; Doherty, Jennifer A; Dork, Thilo; Durst, Matthias; Eccles, Diana; Ekici, Arif B; Embrace Investigators, Study Group Of; Fasching, Peter A; de Fazio, Anna; Fenstermacher, David; Flanagan, James M; Fridley, Brooke L; Friedman, Eitan; Gao, Bo; Gemo Study Collaborators, Study Group Of; Gentry-Maharaj, Aleksandra; Godwin, Andrew K; Goode, Ellen L; Goodman, Marc T; Gross, Jenny; Hansen, Thomas V O; Harnett, Paul R; Hebon Investigators, Study Group Of; Heikkinen, Tuomas; Hein, Rebecca; Hogdall, Claus K; Hogdall, Estrid V; Iversen, Edwin; Jakubowska, Anna; Johnatty, Sharon E; Karlan, Beth Y; Kauff, Noah D; Kaye, Stanley B; Kconfab Investigators, Study Group Of; Kelemen, Linda E; Kiemeney, Lambertus A; Kjaer, Susanne K; Lambrechts, Diether; Lapolla, James P; Lazaro, Conxi; Le, Nhu D; Leminen, Arto; Leunen, Karin; Levine, Douglas A; Lu, Yi; Lundvall, Lene; Macgregor, Stuart; Marees, Tamara; Massuger, Leon; McLaughlin, John; Menon, Usha; Montagna, Marco; Moysich, Kirsten B; Narod, Steven A; Nathanson, Katherine L; Nedergaard, Lotte; Ness, Roberta B; Nevanlinna, Heli A; Nickels, Stefan; Osorio, Ana; Paul, James; Pearce, Celeste Leigh; Phelan, Catherine M; Pike, Malcolm C; Radice, Paolo; Rossing, Maria; Schildkraut, Joellen M; Sellers, Thomas A; Singer, Christian F; Song, Honglin; Stram, Daniel O; Sutphen, Rebecca; Swe-Brca Investigators, Study Group Of; Terry, Kathryn L; Tsai, Ya-Yu; van Altena, Anne M; Vergote, Ignace; Vierkant, Robert A; Vitonis, Allison F; Walsh, Christine; Wang-Gohrke, Shan; Wappenschmidt, Barbara; Wu, Anna H; Ziogas, Argyrios; Berchuck, Andrew; Risch, Harvey; Hansen, Thomas van Overeem; Høgdall, Estrid Vilma Solyom; Nedergaard, Lotte; Rossing, Maria.
I:
Clinical Cancer Research, Bind 17, Nr. 11, 13.04.2011, s. 3742-50.
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
Pharoah, PDP, Palmieri, RT, Ramus, SJ, Gayther, SA, Andrulis, IL, Anton-Culver, HA, Antonenkova, N, Antoniou, AC, Bcfr Investigators, SGO, Beattie, MS, Beckmann, MW, Birrer, MJ, Bogdanova, N, Bolton, KL, Brewster, W, Brooks-Wilson, A, Brown, R, Bützow, R, Caldes, T, Caligo, MA, Campbell, IG, Chang-Claude, J, Chen, YA, Chenevix-Trench, G, Cook, LS, Couch, FJ, Cramer, DW, Cunningham, JM, Despierre, E, Doherty, JA, Dork, T, Durst, M, Eccles, D, Ekici, AB, Embrace Investigators, SGO, Fasching, PA, de Fazio, A, Fenstermacher, D, Flanagan, JM, Fridley, BL, Friedman, E, Gao, B, Gemo Study Collaborators, SGO, Gentry-Maharaj, A, Godwin, AK, Goode, EL, Goodman, MT, Gross, J, Hansen, TVO, Harnett, PR, Hebon Investigators, SGO, Heikkinen, T, Hein, R
, Hogdall, CK, Hogdall, EV, Iversen, E, Jakubowska, A, Johnatty, SE, Karlan, BY, Kauff, ND, Kaye, SB, Kconfab Investigators, SGO, Kelemen, LE, Kiemeney, LA, Kjaer, SK, Lambrechts, D, Lapolla, JP, Lazaro, C, Le, ND, Leminen, A, Leunen, K, Levine, DA, Lu, Y, Lundvall, L, Macgregor, S, Marees, T, Massuger, L, McLaughlin, J, Menon, U, Montagna, M, Moysich, KB, Narod, SA, Nathanson, KL, Nedergaard, L, Ness, RB, Nevanlinna, HA, Nickels, S, Osorio, A, Paul, J, Pearce, CL, Phelan, CM, Pike, MC, Radice, P, Rossing, M, Schildkraut, JM, Sellers, TA, Singer, CF, Song, H, Stram, DO, Sutphen, R, Swe-Brca Investigators, SGO, Terry, KL, Tsai, Y-Y, van Altena, AM, Vergote, I, Vierkant, RA, Vitonis, AF, Walsh, C, Wang-Gohrke, S, Wappenschmidt, B, Wu, AH, Ziogas, A, Berchuck, A, Risch, H, Hansen, TVO, Høgdall, EVS, Nedergaard, L & Rossing, M 2011, '
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing',
Clinical Cancer Research, bind 17, nr. 11, s. 3742-50.
https://doi.org/10.1158/1078-0432.CCR-10-3405,
https://doi.org/10.1158/1078-0432.CCR-10-3405APA
Pharoah, P. D. P., Palmieri, R. T., Ramus, S. J., Gayther, S. A., Andrulis, I. L., Anton-Culver, H. A., Antonenkova, N., Antoniou, A. C., Bcfr Investigators, S. G. O., Beattie, M. S., Beckmann, M. W., Birrer, M. J., Bogdanova, N., Bolton, K. L., Brewster, W., Brooks-Wilson, A., Brown, R., Bützow, R., Caldes, T., ... Rossing, M. (2011).
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing.
Clinical Cancer Research,
17(11), 3742-50.
https://doi.org/10.1158/1078-0432.CCR-10-3405,
https://doi.org/10.1158/1078-0432.CCR-10-3405Vancouver
Author
Pharoah, Paul D P ; Palmieri, Rachel T ; Ramus, Susan J ; Gayther, Simon A ; Andrulis, Irene L ; Anton-Culver, Hoda A ; Antonenkova, Natalia ; Antoniou, Antonis C ; Bcfr Investigators, Study Group Of ; Beattie, Mary S ; Beckmann, Matthias W ; Birrer, Michael J ; Bogdanova, Natalia ; Bolton, Kelly L ; Brewster, Wendy ; Brooks-Wilson, Angela ; Brown, Robert ; Bützow, Ralf ; Caldes, Trinidad ; Caligo, Maria A ; Campbell, Ian G ; Chang-Claude, Jenny ; Chen, Y Ann ; Chenevix-Trench, Georgia ; Cook, Linda S ; Couch, Fergus J ; Cramer, Daniel W ; Cunningham, Julie M ; Despierre, Evelyn ; Doherty, Jennifer A ; Dork, Thilo ; Durst, Matthias ; Eccles, Diana ; Ekici, Arif B ; Embrace Investigators, Study Group Of ; Fasching, Peter A ; de Fazio, Anna ; Fenstermacher, David ; Flanagan, James M ; Fridley, Brooke L ; Friedman, Eitan ; Gao, Bo ; Gemo Study Collaborators, Study Group Of ; Gentry-Maharaj, Aleksandra ; Godwin, Andrew K ; Goode, Ellen L ; Goodman, Marc T ; Gross, Jenny ; Hansen, Thomas V O ; Harnett, Paul R ; Hebon Investigators, Study Group Of ; Heikkinen, Tuomas ; Hein, Rebecca ; Hogdall, Claus K ; Hogdall, Estrid V ; Iversen, Edwin ; Jakubowska, Anna ; Johnatty, Sharon E ; Karlan, Beth Y ; Kauff, Noah D ; Kaye, Stanley B ; Kconfab Investigators, Study Group Of ; Kelemen, Linda E ; Kiemeney, Lambertus A ; Kjaer, Susanne K ; Lambrechts, Diether ; Lapolla, James P ; Lazaro, Conxi ; Le, Nhu D ; Leminen, Arto ; Leunen, Karin ; Levine, Douglas A ; Lu, Yi ; Lundvall, Lene ; Macgregor, Stuart ; Marees, Tamara ; Massuger, Leon ; McLaughlin, John ; Menon, Usha ; Montagna, Marco ; Moysich, Kirsten B ; Narod, Steven A ; Nathanson, Katherine L ; Nedergaard, Lotte ; Ness, Roberta B ; Nevanlinna, Heli A ; Nickels, Stefan ; Osorio, Ana ; Paul, James ; Pearce, Celeste Leigh ; Phelan, Catherine M ; Pike, Malcolm C ; Radice, Paolo ; Rossing, Maria ; Schildkraut, Joellen M ; Sellers, Thomas A ; Singer, Christian F ; Song, Honglin ; Stram, Daniel O ; Sutphen, Rebecca ; Swe-Brca Investigators, Study Group Of ; Terry, Kathryn L ; Tsai, Ya-Yu ; van Altena, Anne M ; Vergote, Ignace ; Vierkant, Robert A ; Vitonis, Allison F ; Walsh, Christine ; Wang-Gohrke, Shan ; Wappenschmidt, Barbara ; Wu, Anna H ; Ziogas, Argyrios ; Berchuck, Andrew ; Risch, Harvey ; Hansen, Thomas van Overeem ; Høgdall, Estrid Vilma Solyom ; Nedergaard, Lotte ; Rossing, Maria. / The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. I: Clinical Cancer Research. 2011 ; Bind 17, Nr. 11. s. 3742-50.
Bibtex
@article{8c9fe7f941bf4a679639c7745667269a,
title = "The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing",
abstract = "PURPOSE: An assay for the single nucleotide polymorphism (SNP) rs61764370 has recently been commercially marketed as a clinical test to aid ovarian cancer risk evaluation in women with family histories of the disease. rs67164370 is in a 3'UTR miRNA binding site of the KRAS oncogene, and is a candidate for epithelial ovarian cancer (EOC) susceptibility. However, only one published paper, analyzing fewer than 1,000 subjects in total, has examined this association. EXPERIMENTAL DESIGN: Risk association was evaluated in 8,669 cases of invasive EOC and 10,012 controls from nineteen studies participating in the Ovarian Cancer Association Consortium, and in 683 cases and 2,044 controls carrying BRCA1 mutations from studies in the Consortium of Investigators of Modifiers of BRCA1/2. Prognosis association was also examined in a subset of five studies with progression-free survival data and eighteen studies with all-cause mortality data.RESULTS: No evidence of association was observed between genotype and risk of unselected EOC (odds ratio (OR)=1.02, 95% confidence interval (CI)=0.95-1.10), serous EOC (OR=1.08, 95%CI=0.98-1.18), familial EOC (OR=1.09, 95%CI=0.78-1.54), or among women carrying deleterious mutations in BRCA1 (OR=1.09, 95%CI=0.88-1.36). There was little evidence for association with survival time among unselected cases (hazard ratio (HR)=1.10, 95%CI=0.99-1.22), among serous cases (HR=1.12, 95%CI=0.99-1.28), or with progression-free survival in 540 cases treated with carboplatin and paclitaxel (HR=1.18, 95%CI=0.93-1.52).CONCLUSIONS: These data exclude the possibility of an association between rs61764370 and a clinically significant risk of ovarian cancer or of familial ovarian cancer. Use of this SNP for ovarian cancer clinical risk prediction therefore appears unwarranted.",
author = "Pharoah, {Paul D P} and Palmieri, {Rachel T} and Ramus, {Susan J} and Gayther, {Simon A} and Andrulis, {Irene L} and Anton-Culver, {Hoda A} and Natalia Antonenkova and Antoniou, {Antonis C} and {Bcfr Investigators}, {Study Group Of} and Beattie, {Mary S} and Beckmann, {Matthias W} and Birrer, {Michael J} and Natalia Bogdanova and Bolton, {Kelly L} and Wendy Brewster and Angela Brooks-Wilson and Robert Brown and Ralf B{\"u}tzow and Trinidad Caldes and Caligo, {Maria A} and Campbell, {Ian G} and Jenny Chang-Claude and Chen, {Y Ann} and Georgia Chenevix-Trench and Cook, {Linda S} and Couch, {Fergus J} and Cramer, {Daniel W} and Cunningham, {Julie M} and Evelyn Despierre and Doherty, {Jennifer A} and Thilo Dork and Matthias Durst and Diana Eccles and Ekici, {Arif B} and {Embrace Investigators}, {Study Group Of} and Fasching, {Peter A} and {de Fazio}, Anna and David Fenstermacher and Flanagan, {James M} and Fridley, {Brooke L} and Eitan Friedman and Bo Gao and {Gemo Study Collaborators}, {Study Group Of} and Aleksandra Gentry-Maharaj and Godwin, {Andrew K} and Goode, {Ellen L} and Goodman, {Marc T} and Jenny Gross and Hansen, {Thomas V O} and Harnett, {Paul R} and {Hebon Investigators}, {Study Group Of} and Tuomas Heikkinen and Rebecca Hein and Hogdall, {Claus K} and Hogdall, {Estrid V} and Edwin Iversen and Anna Jakubowska and Johnatty, {Sharon E} and Karlan, {Beth Y} and Kauff, {Noah D} and Kaye, {Stanley B} and {Kconfab Investigators}, {Study Group Of} and Kelemen, {Linda E} and Kiemeney, {Lambertus A} and Kjaer, {Susanne K} and Diether Lambrechts and Lapolla, {James P} and Conxi Lazaro and Le, {Nhu D} and Arto Leminen and Karin Leunen and Levine, {Douglas A} and Yi Lu and Lene Lundvall and Stuart Macgregor and Tamara Marees and Leon Massuger and John McLaughlin and Usha Menon and Marco Montagna and Moysich, {Kirsten B} and Narod, {Steven A} and Nathanson, {Katherine L} and Lotte Nedergaard and Ness, {Roberta B} and Nevanlinna, {Heli A} and Stefan Nickels and Ana Osorio and James Paul and Pearce, {Celeste Leigh} and Phelan, {Catherine M} and Pike, {Malcolm C} and Paolo Radice and Maria Rossing and Schildkraut, {Joellen M} and Sellers, {Thomas A} and Singer, {Christian F} and Honglin Song and Stram, {Daniel O} and Rebecca Sutphen and {Swe-Brca Investigators}, {Study Group Of} and Terry, {Kathryn L} and Ya-Yu Tsai and {van Altena}, {Anne M} and Ignace Vergote and Vierkant, {Robert A} and Vitonis, {Allison F} and Christine Walsh and Shan Wang-Gohrke and Barbara Wappenschmidt and Wu, {Anna H} and Argyrios Ziogas and Andrew Berchuck and Harvey Risch and Hansen, {Thomas van Overeem} and H{\o}gdall, {Estrid Vilma Solyom} and Lotte Nedergaard and Maria Rossing",
year = "2011",
month = apr,
day = "13",
doi = "10.1158/1078-0432.CCR-10-3405",
language = "English",
volume = "17",
pages = "3742--50",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research (A A C R)",
number = "11",
}
RIS
TY - JOUR
T1 - The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing
AU - Pharoah, Paul D P
AU - Palmieri, Rachel T
AU - Ramus, Susan J
AU - Gayther, Simon A
AU - Andrulis, Irene L
AU - Anton-Culver, Hoda A
AU - Antonenkova, Natalia
AU - Antoniou, Antonis C
AU - Bcfr Investigators, Study Group Of
AU - Beattie, Mary S
AU - Beckmann, Matthias W
AU - Birrer, Michael J
AU - Bogdanova, Natalia
AU - Bolton, Kelly L
AU - Brewster, Wendy
AU - Brooks-Wilson, Angela
AU - Brown, Robert
AU - Bützow, Ralf
AU - Caldes, Trinidad
AU - Caligo, Maria A
AU - Campbell, Ian G
AU - Chang-Claude, Jenny
AU - Chen, Y Ann
AU - Chenevix-Trench, Georgia
AU - Cook, Linda S
AU - Couch, Fergus J
AU - Cramer, Daniel W
AU - Cunningham, Julie M
AU - Despierre, Evelyn
AU - Doherty, Jennifer A
AU - Dork, Thilo
AU - Durst, Matthias
AU - Eccles, Diana
AU - Ekici, Arif B
AU - Embrace Investigators, Study Group Of
AU - Fasching, Peter A
AU - de Fazio, Anna
AU - Fenstermacher, David
AU - Flanagan, James M
AU - Fridley, Brooke L
AU - Friedman, Eitan
AU - Gao, Bo
AU - Gemo Study Collaborators, Study Group Of
AU - Gentry-Maharaj, Aleksandra
AU - Godwin, Andrew K
AU - Goode, Ellen L
AU - Goodman, Marc T
AU - Gross, Jenny
AU - Hansen, Thomas V O
AU - Harnett, Paul R
AU - Hebon Investigators, Study Group Of
AU - Heikkinen, Tuomas
AU - Hein, Rebecca
AU - Hogdall, Claus K
AU - Hogdall, Estrid V
AU - Iversen, Edwin
AU - Jakubowska, Anna
AU - Johnatty, Sharon E
AU - Karlan, Beth Y
AU - Kauff, Noah D
AU - Kaye, Stanley B
AU - Kconfab Investigators, Study Group Of
AU - Kelemen, Linda E
AU - Kiemeney, Lambertus A
AU - Kjaer, Susanne K
AU - Lambrechts, Diether
AU - Lapolla, James P
AU - Lazaro, Conxi
AU - Le, Nhu D
AU - Leminen, Arto
AU - Leunen, Karin
AU - Levine, Douglas A
AU - Lu, Yi
AU - Lundvall, Lene
AU - Macgregor, Stuart
AU - Marees, Tamara
AU - Massuger, Leon
AU - McLaughlin, John
AU - Menon, Usha
AU - Montagna, Marco
AU - Moysich, Kirsten B
AU - Narod, Steven A
AU - Nathanson, Katherine L
AU - Nedergaard, Lotte
AU - Ness, Roberta B
AU - Nevanlinna, Heli A
AU - Nickels, Stefan
AU - Osorio, Ana
AU - Paul, James
AU - Pearce, Celeste Leigh
AU - Phelan, Catherine M
AU - Pike, Malcolm C
AU - Radice, Paolo
AU - Rossing, Maria
AU - Schildkraut, Joellen M
AU - Sellers, Thomas A
AU - Singer, Christian F
AU - Song, Honglin
AU - Stram, Daniel O
AU - Sutphen, Rebecca
AU - Swe-Brca Investigators, Study Group Of
AU - Terry, Kathryn L
AU - Tsai, Ya-Yu
AU - van Altena, Anne M
AU - Vergote, Ignace
AU - Vierkant, Robert A
AU - Vitonis, Allison F
AU - Walsh, Christine
AU - Wang-Gohrke, Shan
AU - Wappenschmidt, Barbara
AU - Wu, Anna H
AU - Ziogas, Argyrios
AU - Berchuck, Andrew
AU - Risch, Harvey
AU - Hansen, Thomas van Overeem
AU - Høgdall, Estrid Vilma Solyom
AU - Nedergaard, Lotte
AU - Rossing, Maria
PY - 2011/4/13
Y1 - 2011/4/13
N2 - PURPOSE: An assay for the single nucleotide polymorphism (SNP) rs61764370 has recently been commercially marketed as a clinical test to aid ovarian cancer risk evaluation in women with family histories of the disease. rs67164370 is in a 3'UTR miRNA binding site of the KRAS oncogene, and is a candidate for epithelial ovarian cancer (EOC) susceptibility. However, only one published paper, analyzing fewer than 1,000 subjects in total, has examined this association. EXPERIMENTAL DESIGN: Risk association was evaluated in 8,669 cases of invasive EOC and 10,012 controls from nineteen studies participating in the Ovarian Cancer Association Consortium, and in 683 cases and 2,044 controls carrying BRCA1 mutations from studies in the Consortium of Investigators of Modifiers of BRCA1/2. Prognosis association was also examined in a subset of five studies with progression-free survival data and eighteen studies with all-cause mortality data.RESULTS: No evidence of association was observed between genotype and risk of unselected EOC (odds ratio (OR)=1.02, 95% confidence interval (CI)=0.95-1.10), serous EOC (OR=1.08, 95%CI=0.98-1.18), familial EOC (OR=1.09, 95%CI=0.78-1.54), or among women carrying deleterious mutations in BRCA1 (OR=1.09, 95%CI=0.88-1.36). There was little evidence for association with survival time among unselected cases (hazard ratio (HR)=1.10, 95%CI=0.99-1.22), among serous cases (HR=1.12, 95%CI=0.99-1.28), or with progression-free survival in 540 cases treated with carboplatin and paclitaxel (HR=1.18, 95%CI=0.93-1.52).CONCLUSIONS: These data exclude the possibility of an association between rs61764370 and a clinically significant risk of ovarian cancer or of familial ovarian cancer. Use of this SNP for ovarian cancer clinical risk prediction therefore appears unwarranted.
AB - PURPOSE: An assay for the single nucleotide polymorphism (SNP) rs61764370 has recently been commercially marketed as a clinical test to aid ovarian cancer risk evaluation in women with family histories of the disease. rs67164370 is in a 3'UTR miRNA binding site of the KRAS oncogene, and is a candidate for epithelial ovarian cancer (EOC) susceptibility. However, only one published paper, analyzing fewer than 1,000 subjects in total, has examined this association. EXPERIMENTAL DESIGN: Risk association was evaluated in 8,669 cases of invasive EOC and 10,012 controls from nineteen studies participating in the Ovarian Cancer Association Consortium, and in 683 cases and 2,044 controls carrying BRCA1 mutations from studies in the Consortium of Investigators of Modifiers of BRCA1/2. Prognosis association was also examined in a subset of five studies with progression-free survival data and eighteen studies with all-cause mortality data.RESULTS: No evidence of association was observed between genotype and risk of unselected EOC (odds ratio (OR)=1.02, 95% confidence interval (CI)=0.95-1.10), serous EOC (OR=1.08, 95%CI=0.98-1.18), familial EOC (OR=1.09, 95%CI=0.78-1.54), or among women carrying deleterious mutations in BRCA1 (OR=1.09, 95%CI=0.88-1.36). There was little evidence for association with survival time among unselected cases (hazard ratio (HR)=1.10, 95%CI=0.99-1.22), among serous cases (HR=1.12, 95%CI=0.99-1.28), or with progression-free survival in 540 cases treated with carboplatin and paclitaxel (HR=1.18, 95%CI=0.93-1.52).CONCLUSIONS: These data exclude the possibility of an association between rs61764370 and a clinically significant risk of ovarian cancer or of familial ovarian cancer. Use of this SNP for ovarian cancer clinical risk prediction therefore appears unwarranted.
U2 - 10.1158/1078-0432.CCR-10-3405
DO - 10.1158/1078-0432.CCR-10-3405
M3 - Journal article
C2 - 21385923
VL - 17
SP - 3742
EP - 3750
JO - Clinical Cancer Research
JF - Clinical Cancer Research
SN - 1078-0432
IS - 11
ER -
